Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: An opportunity for stewardship

Keyphrases

• Clinical Outcomes 100%
• Adult Patients 100%
• Viral Pneumonia 100%
• Stewardship 100%
• Long-course 100%
• Short Course 60%
• Multidrug-resistant Organisms 60%
• Course Group 60%
• Viral Infection 40%
• Respiratory Viral Panel 40%
• Antibacterial Ability 40%
• Etiology 20%
• Pneumonia 20%
• Retrospective Cohort Study 20%
• Virus 20%
• Hospitalized Patients 20%
• In-hospital Mortality 20%
• Vancomycin 20%
• Polymerase Chain Reaction 20%
• Single Center 20%
• Multiplex 20%
• Azithromycin 20%
• Days of Therapy 20%
• Respiratory Viruses 20%
• Radiological Findings 20%
• Linezolid 20%
• Meropenem 20%
• Influenza 20%
• Empirical Therapy 20%
• Viral Pathogens 20%
• Enterovirus 20%
• Advanced Technologies 20%
• March 2013 20%
• Cefepime 20%
• Outside Hospital 20%
• Short-term Treatment 20%
• Molecular Assay 20%
• Rhinovirus 20%
• Parainfluenza 20%
• Subsequent Infection 20%
• Active Malignancy 20%
• Pneumonia Etiology 20%
• Panel Report 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiinfective Agent 100%
• Virus Pneumonia 100%
• Infection 50%
• Virus Infection 33%
• Cohort Study 16%
• Infectious Agent 16%
• Hospital Mortality 16%
• Azithromycin 16%
• Linezolid 16%
• Vancomycin 16%
• Respiratory Virus 16%
• Rhinovirus 16%
• Cefepime 16%
• Meropenem 16%
• Enterovirus 16%
• Short Course Therapy 16%

Immunology and Microbiology

• Infection 100%
• Viral Disease 66%
• Infectious Agent 33%
• Enterovirus 33%
• Respiratory Virus 33%
• Influenza 33%
• Hospital Mortality 33%
• Parainfluenza 33%
• Rhinovirus 33%
• Polymerase Chain Reaction 33%
• Virus 33%